Does Rallies show Form 4 insider transactions for IPSC?

Yes. Rallies tracks IPSC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IPSC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IPSC. It does not provide personalized investment advice.

IPSC (Century Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Century Therapeutics, Inc. Common Stock (IPSC) is a publicly traded Healthcare sector company. As of May 21, 2026, IPSC trades at $2.25 with a market cap of $411.21M and a P/E ratio of -15.75. IPSC moved +6.37% today. Year to date, IPSC is +126.27%; over the trailing twelve months it is +275.00%. Its 52-week range spans $0.34 to $3.04. Analyst consensus is strong buy with an average price target of $5.20. Rallies surfaces IPSC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IPSC stock inside the company?

Recent IPSC insider activity includes Carr Douglas sold 264, Carr Douglas sold 7.04K, Russotti Gregory sold 10.08K, Russotti Gregory sold 479, and Carr Douglas sold 247. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IPSC Key Metrics

Key financial metrics for IPSC
Metric	Value
Price	$2.25
Market Cap	$411.21M
P/E Ratio	-15.75
EPS	$-0.14
Dividend Yield	0.00%
52-Week High	$3.04
52-Week Low	$0.34
Volume	0
Avg Volume	0
Revenue (TTM)	$109.16M
Net Income	$-9.58M
Gross Margin	0.00%

Recent IPSC Insider Trades

Carr Douglas sold 264 (~$618.024) on May 4, 2026.
Carr Douglas sold 7.04K (~$17.95K) on Mar 12, 2026.
Russotti Gregory sold 10.08K (~$25.68K) on Mar 12, 2026.
Russotti Gregory sold 479 (~$1.21K) on Mar 9, 2026.
Carr Douglas sold 247 (~$626.392) on Mar 9, 2026.

Latest IPSC News

Century Therapeutics Eyes IND Filing for Diabetes Therapy, Holds $217M Runway — May 13, 2026
Century Therapeutics Raises $135M, Plans Q4 2026 IND for Cell Therapy — Mar 12, 2026

IPSC Analyst Consensus

4 analysts cover IPSC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.20.

Common questions about IPSC

Who is trading IPSC stock inside the company?: Recent IPSC insider activity includes Carr Douglas sold 264, Carr Douglas sold 7.04K, Russotti Gregory sold 10.08K, Russotti Gregory sold 479, and Carr Douglas sold 247. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IPSC?: Yes. Rallies tracks IPSC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IPSC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IPSC. It does not provide personalized investment advice.